Insider Trading Alert - SPLK, SGMO And CMLP Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Thursday, April 17, 2014, 85 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $53.41 to $64,010,000.00.

Highlighted Stocks Traded by Insiders:

Splunk (SPLK) - FREE Research Report

Neustaetter Thomas M, who is Director at Splunk, sold 1,500 shares at $64.16 on April 17, 2014. Following this transaction, the Director owned 53,603 shares meaning that the stake was reduced by 2.72% with the 1,500-share transaction.

The shares most recently traded at $63.25, down $0.91, or 1.43% since the insider transaction. Historical insider transactions for Splunk go as follows:

  • 4-Week # shares sold: 50,700
  • 12-Week # shares sold: 193,724
  • 24-Week # shares sold: 277,859

The average volume for Splunk has been 2.9 million shares per day over the past 30 days. Splunk has a market cap of $7.8 billion and is part of the technology sector and computer software & services industry. Shares are down 4.12% year-to-date as of the close of trading on Thursday.

Splunk, Inc. provides software solutions that provide real-time operational intelligence in the United States and internationally. Currently, there are 15 analysts who rate Splunk a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SPLK - FREE

TheStreet Quant Ratings rates Splunk as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and feeble growth in its earnings per share. Get the full Splunk Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Sangamo BioSciences (SGMO) - FREE Research Report

Lanphier Edward O Ii, who is President & CEO at Sangamo BioSciences, sold 25,000 shares at $14.20 on April 17, 2014. Following this transaction, the President & CEO owned 1.6 million shares meaning that the stake was reduced by 1.57% with the 25,000-share transaction.

The shares most recently traded at $13.82, down $0.38, or 2.75% since the insider transaction. Historical insider transactions for Sangamo BioSciences go as follows:

  • 4-Week # shares sold: 2,000
  • 12-Week # shares sold: 2,000
  • 24-Week # shares sold: 2,000

The average volume for Sangamo BioSciences has been 1.6 million shares per day over the past 30 days. Sangamo BioSciences has a market cap of $933.0 million and is part of the health care sector and drugs industry. Shares are up 0.72% year-to-date as of the close of trading on Thursday.

Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Currently, there are 3 analysts who rate Sangamo BioSciences a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SGMO - FREE

TheStreet Quant Ratings rates Sangamo BioSciences as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share. Get the full Sangamo BioSciences Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Crestwood Midstream Partners (CMLP) - FREE Research Report

Sherman John J, who is Director at Crestwood Midstream Partners, sold 120,000 shares at $23.74 on April 17, 2014. Following this transaction, the Director owned 226,790 shares meaning that the stake was reduced by 34.6% with the 120,000-share transaction.

The shares most recently traded at $22.91, down $0.83, or 3.6% since the insider transaction. Historical insider transactions for Crestwood Midstream Partners go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 3,627
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 3,627
  • 24-Week # shares bought: 20,000
  • 24-Week # shares sold: 3,627

The average volume for Crestwood Midstream Partners has been 963,500 shares per day over the past 30 days. Crestwood Midstream Partners has a market cap of $4.3 billion and is part of the basic materials sector and energy industry.

Crestwood Midstream Partners LP is engaged in the gathering, processing, treating, compression, storage, and transportation of natural gas; storage and transportation of natural gas liquids (NGLs); and gathering, storage, and terminalling of crude oil in the United States.

Exclusive Offer: Get the latest Stock Analysis on CMLP - FREE

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists